GNT Animal Health


Our Mission of GNT Animal Health

We aim to offer products that are more than just effective tools for the treatment and control of animal disease.



Brown-colored round chewable tablet
Active Ingredient
Control of clinical signs associated with canine cognitive dysfunction syndrome
Dosage / Administration
Refer to the labelling (attached file) and administer the pill once a day according to the body weight.
Avoid direct sunlight and store at room temperature (1~30℃).
30 Tablets / package
What is GedaCure®?
GedaCure® is the world's first canine cognitive dysfunction syndrome treatment.
The name is a combination of Gedächtnis, a German word meaning - "memory".
Also, Cure an English word meaning - "healing or treating".
As the number of the family with companion animal increases, veterinary medicine has developed, leading the life expectancy of dogs increased every year.
As dog’s lifespan increased, canine cognitive dysfunction syndrome has also increased, making owners seek more attention to their dogs.
GedaCure® is a new drug that treats dogs with cognitive dysfunction syndrome by effectively
removing oxidative stress and inflammation in their brain, thereby preventing the death of brain cells.
Active Ingredient
Crisdesalazine, the active ingredient of GedaCure®, is a new drug with dual pharmacological mechanisms acting as a powerful antioxidant action and an anti-inflammatory action. It has been proven that crisdesalazine improves cognitive function by effectively preventing both the oxidative stress and inflammation in brain, leading to protecting neurons in transgenic mouse models of Alzheimer’s disease.
Crisdesalazine reduces oxidative stress in neuronal cells
by removing hydroxyl radicals.
Crisdesalazine is an mPGES-1 inhibitor that reduces inflammation
in the brain by inhibiting PGE2 synthesis.
Shin et al. Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety
and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2012; 122(5): 952-961
After the oral administration of crisdesalazine once daily at 200 mg/kg which is 40 times higher than the recommended dose in dogs for 13 weeks, no significant differences were observed between the dogs treated with crisdesalazine and the normal control group dogs treated with its vehicle in vital signs (blood pressure, heart rate, etc.), electrocardiogram, ophthalmic examination, complete blood cell count, serum chemistry, urinalysis, and the histological examination of other organs.
Additionally, no significantly abnormal findings were observed after administration of crisdesalazine in our phase III clinical trial for approval when the above examinations were conducted for dogs with cognitive dysfunction syndrome.
We compared the gastrointestinal side effects after the oral administration of high doses of crisdesalazine and several NSAIDs which are the representative anti-inflammatory drugs in rats. Rats that were treated with aspirin, ibuprofen, or celecoxib showed significant gastrointestinal bleeding, whereas the other rats treated with crisdesalazine did not show any gastrointestinal side effects even with the administration of 1000 mg/kg dose that is 200 times higher than the recommended dose.
1000 mg/kg
  • Aspirin
    300 mg/kg
  • Ibuprofen
    300 mg/kg
  • Celecoxib
    1000 mg/kg
Brand Identity

Combination of G of "Geda" and C of "Cure"

Meaning “a fundamental treatment” by placing “Cure” in the center.
Meaning “cure the memory” by connecting the C (Cure) from the G (Gedächtnis, memory)
The overall shape is a combination of a circle and a straight line away from a formalized circle, with a repetitive and stable pattern.